Pages
- 2007 News Releases
- 2007 News Releases
- 2008 News Releases
- 2008 News Releases
- 2009 News Releases
- 2009 News Releases
- 2010 News Releases
- 2010 News Releases
- 2011 News Releases
- 2011 News Releases
- 2012 News Releases
- 2012 News Releases
- 2013 News Releases
- 2013 News Releases
- 2013 News Releases
- 2014 News Releases
- 2015 News Releases
- 2016 News Releases
- 2017 News Releases
- 2018 News Releases
- About iCo
- About Vancouver
- Accomplishments
- AGM
- Alliances & Global Licensing
- Board of Directors
- Careers
- Careers
- Careers
- Clinical Trials
- Contact Us
- Corporate Overview
- Corporate Overview
- Corporate Overview
- Corporate Overview
- Corporate Overview
- Corporate Overview
- Corporate Overview
- Corporate Video
- Current Assets
- Development Programs
- Development Programs
- Disclaimer
- Events
- FAQ
- Get In Touch
- How to Make Sure that Generic Drugs are Safe for Your Health?
- iCo 007
- iCo Therapeutics – Your Health Is Your Most Precious Asset
- iCo-008
- Investor Information: Articles
- Investor Information: Financial Information
- Investor Information: Presentations
- Investor Information: Press Releases
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Investor Relations
- Leadership and Board of Directors
- Liver Failure – Symptoms, Medications, Prevention
- Management Team
- Media Coverage
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News and Media
- News Releases
- Newsroom
- Oral Amphotericin B (“Amp B”)
- Our Business Model
- Overview
- Overview
- Partnering
- Partnering Strategy
- Pipeline
- Pipeline
- Pipeline
- Pipeline
- Pipeline
- Pipeline
- Presentations
- Press Releases
- Professional Advisors
- Professional Advisors
- Public information on the iDEAL study
- Reports & Financials
- Research
- Science
- Science
- Sitemap
- Strategic Advisory Board
- Strategic Advisory Board
- Terms of Use
- Upcoming Events
Posts by category
- Category: 2007
- iCo Therapeutics Inc. and Beanstalk Capital Ltd. Announce Completion of Arrangement
- Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
- Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc.
- Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
- iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema
- iCo Therapeutics Announces Licensing Deal
- Cambridge Antibody Tech. licenses monoclonal antibody for treatment of allergy disorders to iCo
- Category: 2008
- iCo Therapeutics Oral Amphotericin B Poster at AAPS
- iCo Therapeutics Third Quarter Financial Results
- iCo Therapeutics Oral Amphotericin B Effective Against Visceral Leishmaniasis
- iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Pharmacokinetic Results
- iCo Therapeutics Selected as Canada’s Top 10TM Competition Winner
- iCo Therapeutics to Present at BioContact Québec
- iCo Therapeutics Provides Interim Trial Results (Diffuse Diabetic Macular Edema)
- iCo Therapeutics Outlines Steps to First iCo-009 Human Clinical Trial
- iCo Therapeutics Second Quarter Financial Results
- iCo Therapeutics Appoints Mr. Noel Hall and Dr. Christian Fibiger to Board
- iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results
- iCo Therapeutics Closes $1,140,450 Financing
- iCo Therapeutics Announces $1,140,450 Financing
- iCo Therapeutics First Quarter Financial Results
- iCo Therapeutics Acquires Worldwide Rights to iCo-009 (Oral Amphotericin B)
- iCo Therapeutics to Present at BioFinance 2008
- iCo Therapeutics Year-End 2007 Financial Results
- iCo Therapeutics iCo-007 Diabetic Macular Edema Poster Presentation at ARVO
- iCo Therapeutics Announces iCo-009 (Oral Amphotericin B) FDA Meeting
- iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal
- iCo Therapeutics Provides iCo-008 Phase II Clinical Update
- iCo Therapeutics Announces CMO Invited to Present at International Ocular Conference
- iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Update
- Category: 2009
- iCo Therapeutics Grants Options to Directors, Officers and Employees
- iCo Therapeutics Provides Phase 1 DME Clinical Trial Update and Phase 2 Trial Guidance
- iCo Therapeutics iCo-007 Overview to be Presented at the 8th International Symposium on Ocular Pharmacology and Therapeutics
- iCo Therapeutics Q3 2009 Financial Results
- iCo Therapeutics Completes Final Tranche of $4,000,000 Brokered Private Placement
- iCo Therapeutics Completes First Tranche of Brokered Private Placement
- iCo Therapeutics Announces $4,000,000 Brokered Private Placement
- iCo Therapeutics Signs Collaboration Agreement with The Consortium for Parasitic Drug Development
- iCo Therapeutics Q2 2009 Financial Results
- iCo Therapeutics Appoints Infectious Disease MD to Scientific Advisory Board
- iCo Therapeutics Closes Non-Brokered Private Placement
- iCo Therapeutics Diabetic Macular Edema Clinical Trial Update
- iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment
- iCo Therapeutics Positive Oral Amphotericin B Data Published in the Journal of Infectious Diseases
- Shareholders Approve All Resolutions at iCo Therapeutics Annual General Meeting
- iCo Therapeutics Q1 2009 Financial Results
- iCo Therapeutics Year-End 2008 Financial Results
- iCo Therapeutics to Present at BioFinance 2009
- iCo Therapeutics Oral Anti-Parasitic Drug to be Presented at Global Health Symposia
- iCo Therapeutics iCo-007 Second Cohort Results to be Presented at Cleveland Clinic Ocular Conference
- iCo Therapeutics Grants Options to New Directors
- iCo Therapeutics iCo-007 Results to be Presented at Prestigious Ocular Conference
- iCo Therapeutics Oral Amphotericin B Published in Leading Journal
- iCo Therapeutics Closes $1.3 Million Private Placement
- iCo Therapeutics Closes First Tranche of Non-Brokered Private Placement
- Category: 2010
- iCo Therapeutics Extends Investor Relations Engagement with The Trout Group
- iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus Royalties
- iCo Therapeutics Reports Third Quarter 2010 Financial Results
- iCo Therapeutics Selected as Canada’s Top 10TM Competition Winner
- iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status
- iCo Therapeutics Appoints Infectious Disease Experts to Scientific Advisory Board
- iCo Therapeutics Announces Second Quarter 2010 Financial Results
- iCo Therapeutics Inc. receives Health Canada Clearance to Conduct Phase II DME Trial with iCo-007
- iCo Therapeutics Inc. enters into Investor Relations Engagements with The Trout Group and Sector Speak
- iCo Therapeutics Announces First Quarter 2010 Financial Results
- iCo Therapeutics Inc. enters into Technology Transfer Agreement with Isis Pharmaceuticals, Inc. for iCo-007
- iCo Therapeutics iCo-007 Phase I Clinical Trial Meets Primary Endpoint
- iCo Therapeutics Announces Year-End 2009 Financial Results
- iCo Therapeutics Inc. engages Susan Koppy to spearhead iCo-007 out-licensing
- iCo-007 for Diffuse Diabetic Macular Edema to be Presented at Retinal Physician Symposium 2010
- iCo Therapeutics Inc. Recognized by BIOTECanada with Gold Leaf Award
- iCo-007 for Diabetic Macular Edema to be Presented at Angiogenesis 2010: Clinical Trials
- iCo Therapeutics Announces Exercise of Warrants
- Category: 2011
- iCo Therapeutics Announces Execution of Equity Line Facility Agreement
- iCo Therapeutics Announces Third Quarter 2011 Financial Results
- iCo Therapeutics Closes $1,115,000 Non-Brokered Private Placement
- iCo Therapeutics Oral Amphotericin B Delivery System to be Presented at AAPS
- iCo Therapeutics CEO to Present at the Ophthalmology Innovation Summit
- iCo Therapeutics Grants Options to Directors, Officers and Employees
- iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema
- iCo Therapeutics CEO to Present & Act as Co-Chairperson at the 4th Annual Drug Repositioning and Pipeline Enhancement Conference
- iCo Therapeutics CEO to Present & Act as Co-Chairperson at the 4th Annual Drug Repositioning and Pipeline Enhancement Conference
- iCo Therapeutics Announces Second Quarter 2011 Financial Results
- iCo Therapeutics Announces Key iCo-007 Clinical Development Milestone
- iCo Therapeutics Announces Resignation of John Clement, Chief Technology and Development Officer and Director
- iCo Therapeutics Engages The Equicom Group
- iCo Therapeutics CMO to Present at The Drug Repositioning Conference
- iCo Therapeutics Announces First Quarter 2011 Financial Results
- iCo Therapeutics Executes Bertilimumab License with Immune Pharmaceuticals
- iCo Therapeutics CEO to Present & Participate in Panel at BioFinance 2011
- iCo Therapeutics Inc. Engages Ora for Ophthalmic Clinical & Regulatory Guidance
- iCo Therapeutics Announces Year-End 2010 Financial Results
- iCo Therapeutics Inc. Secures $10 Million Equity Line Facility
- iCo Therapeutics Inc. iCo-007 Program to be Presented & CEO to Sit on Panel at Retinal Physician Symposium 2011
- iCo Therapeutics Inc. Completes iCo-007 Phase 2 Clinical Supply Manufacturing
- iCo Therapeutics Announces Year-End 2010 Financial Results
- iCo Therapeutics Inc. Secures $10 Million Equity Line Facility
- iCo Therapeutics Inc. iCo-007 Program to be Presented & CEO to Sit on Panel at Retinal Physician Symposium 2011
- Category: 2012
- iCo Therapeutics Announces Third Quarter 2012 Financial Results
- iCo Therapeutics’ Oral Amphotericin B Delivery System to be Presented at AAPS with Updated Patent Position
- iCo Therapeutics to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
- iCo Therapeutics Announces Second Quarter 2012 Financial Results
- iCo Therapeutics Closes $2.55 Million Financing
- iCo Therapeutics to Raise $2.55 Million
- iCo Therapeutics Announces Overnight Marketed Equity Offering
- iCo Therapeutics receives funding from the Government of Canada for the pre-clinical and clinical development of its Oral Amphotericin B Delivery System for the treatment of HIV/AIDS
- iCo Therapeutics Announces First Quarter 2012 Financial Results
- iCo Therapeutics Announces Year End 2011 Financial Results
- iCo Therapeutics and JDRF Team Up to Support Phase II Clinical Trial iDEAL for Diabetic Macular Edema
- iCo Therapeutics CEO to Present at Retinal Physician Symposium 2012
- iCo Therapeutics Appoints Douglas Janzen to Board of Directors
- iCo Therapeutics Retains Crescendo Communications
- Category: 2013
- iCo Therapeutics Announces Overnight Marketed Equity Offering
- iCo Therapeutics Begins Trading on the OTCQX Marketplace
- iCo Therapeutics Announces Program and Intellectual Property Advancements for Oral Amphotericin B
- iCo Therapeutics To Present At Jefferies Ophthalmic Therapeutic Summit
- iCo Therapeutics Announces Third Quarter 2013 Financial Results
- iCo Therapeutics to Present at the 6th Annual LD MICRO
- iCo Therapeutics Announces Warrant Exercise
- iCo Therapeutics to Present at the Ophthalmology Innovation Summit
- iCo Therapeutics Grants Options to a Director
- iCo Therapeutics to Present at the Rodman & Renshaw 2013 Annual Global Investment Conference
- iCo Therapeutics Announces Second Quarter 2013 Financial Results
- iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema
- iCo Therapeutics Announces First Quarter 2013 Financial Results
- iCo Therapeutics Announces Director Election Results from its Annual General Meeting of Shareholders
- iCo Therapeutics Closes $3.4 Million Financing
- iCo Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Conference
- iCo Therapeutics to Raise $3.2 Million
- iCo Therapeutics Announces Year End 2012 Financial Results
- iCo Therapeutics Ranked Number One in Technology & Life Sciences on 2013 TSX Venture 50
- iCo Therapeutics to Present at the 15th Annual BIO CEO & Investor Conference
- iCo Therapeutics Grants Options to Directors, Officers and Employees
- iCo Therapeutics Announces Positive iCo-007 Phase 2 Clinical Update
- Category: 2014
- iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update
- iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS
- iCo Therapeutics Announces Advancement of Oral Amphotericin B Program
- iCo Therapeutics Announces Second Quarter 2014 Financial Results
- iCo Therapeutics Announces Positive Oral Amphotericin B Study Results
- iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders
- iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema
- iCo Therapeutics Announces First Quarter 2014 Financial Results
- iCo Therapeutics Announces Poster Presentation at ARVO
- iCo Therapeutics Announces Year End 2013 Financial Results
- iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study
- iCo Therapeutics Announces DTC Approval
- iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing
- iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing
- iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering
- Category: 2015
- iCo Therapeutics Announces Changes to Board of Directors
- iCo Therapeutics Announces Third Quarter 2015 Financial Results
- iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program
- iCo Therapeutics Announces Second Quarter 2015 Financial Results
- iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders
- iCo Therapeutics Announces First Quarter 2015 Financial Results
- iCo Therapeutics Announces Year End 2014 Financial Results
- Category: 2016
- CLARIFICATION iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program
- iCo Therapeutics Announces Third Quarter 2016 Financial Results
- iCo Therapeutics Announces World Wide Exclusive Option and EU License Rights with Laboratorios SALVAT for Novel Glaucoma Asset
- iCo Therapeutics Announces Second Quarter 2016 Financial Results
- iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders
- iCo Therapeutics Announces Year End 2015 Financial Results
- iCo Therapeutics Inc. Announces Grant of Stock Options and Recent CEO Share Purchases
- iCo Strategic Reorganization
- Category: 2017
- iCo Therapeutics Announces Third Quarter 2017 Financial Results
- iCo Therapeutics Announces Ethics Approval for its Oral Amphotericin B Phase 1 Clinical Study
- iCo Therapeutics Announces Upcoming Presentations and Meetings
- iCo Therapeutics Announces Second Quarter 2017 Financial Results
- iCo Therapeutics Inc. Approves Advance Notice Policy
- iCo Therapeutics Announces Election of Directors
- iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset
- iCo Therapeutics Announces Positive Oral Amphotericin Study
- iCo Therapeutics Announces First Quarter 2017 Financial Results
- iCo Therapeutics Announces Year End 2016 Financial Results
- iCo Therapeutics Inc. Announces No Material Change
- Category: 2018
- iCo Therapeutics Announces Third Quarter 2018 Financial Results And Corporate Update
- iCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study
- iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board
- iCo Therapeutics Provides Corporate Update
- iCo Therapeutics Announces Additional Positive Pharmacokinetic Results and Presentation at Global Investment Conference
- iCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update
- iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials – Phase 1 Oral Amphotericin B
- iCo Therapeutics Announces Positive Clinical Outcome – Primary Endpoint Met in Phase 1 Oral Amphotericin B Study
- iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment
- iCo Therapeutics Announces First Quarter 2018 Financial Results And Update On Phase 1 Clinical Trial
- iCo Therapeutics Announces Year End 2017 Financial Results
- iCo Therapeutics Announces Major Milestone – Dosing of First Patient for its Oral Amphotericin B Phase 1 Clinical Study
- Category: 2019
- iCo Therapeutics Announces Completion of Sub-license Transfer and Full Dosing of Fifty Per Cent of Phase 1b Subjects
- iCo Therapeutics Engages Ora for iCo-008 Ophthalmic Strategy and Pre Phase II FDA Meeting
- iCo Therapeutics Announces Dosing of First Full Cohort in Second Oral Amphotericin B Study
- Alexion Pharmaceuticals – iCo’s New Partner for the Development and Commercialization of iCo-008
- iCo Therapeutics Inc. Provides an Update Regarding Oral Amphotericin Study, Marketing and Partnering Activities
- iCo Therapeutics Provides a Corporate Update
- iCo Therapeutics Announces Second Quarter 2019
- iCo Therapeutics Inc. Announces the Issuance of 41,200,000 Units Pursuant to its Non-Brokered Private Placement
- iCo Therapeutics Provides Corporate Update
- iCo Therapeutics Announces AGM Voting Results
- iCo Therapeutics Announces First Quarter 2019 Financial Results
- iCo Therapeutics Announces 2018 Year End Financial
- News & Releases
- iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement
- iCo Therapeutics Inc. Announces Notice of Termination of Sub License for Bertilimumab (iCo-008)
- iCo Therapeutics Inc. Announces Upsizing of Non-Brokered Private Placement to $1,250,000 CDN
- iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-Brokered Private Placement
- News Releases
- iCo Therapeutics Inc. Announces Non-Brokered Private Placement to Raise C$750,000
- Category: 2020
- iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical
- iCo Therapeutics Announces Third Quarter 2020 Financial Results
- iCo Therapeutics Announces Option Grants
- iCo Therapeutics Inc. Announces That Oral Amphotericin B (iCo-019) Results Will Be Highlighted During the American Association of Pharmaceutical Scientists (AAPS) Virtual Meeting October 26 – November 3rd, 2020
- iCo Therapeutics Announces Second Quarter 2020 Financial Results
- iCo Therapeutics Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases Journal
- iCo Therapeutics Announces First Quarter 2020 Financial Results
- iCo Therapeutics Announces Oral Amphotericin B (iCo-019) Results to be Presented at Prestigious American Pharmaceutical Sciences Meeting and Discussion Updates
- iCo Therapeutics Announces Q1 Interim Filing Update
- iCo Therapeutics Announces 2019 Year End Financial Results
- iCo Therapeutics Announces Annual Filing Update
- iCo Therapeutics Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research
- iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research
- iCo Therapeutics Announces Leadership Changes
- iCo Therapeutics Successfully Concludes Phase 1b Clinical Study Announces Positive Primary End Point for Oral Amphotericin B
- iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing and Follow Up
- iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing & Follow Up
- iCo Therapeutics Inc. Proposes to Re-Price Warrants
- iCo Therapeutics Announces Option Grants
- iCo Therapeutics Announces Option Grants
- Category: 2021
- Category: Press Releases